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 Introduction  
 Atherosclerosis is a chronic, progressive vascular dis-
order characterized by infiltration of inflammatory cells 
from circulating blood, including monocyte-derived 
foam cells and extracellular matrices  [1] . Once in the vas-
cular wall, they trigger and propagate inflammatory re-
actions that are crucial not only in initiation of athero-
sclerosis, but also in progression of atheromatous plaques 
and regulation of plaque stability. Despite a wealth of 
knowledge on the involvement of infiltrating blood cells 
in atherosclerosis, little is known about the relationship 
between circulating blood cell activation and carotid ar-
tery wall architecture/atherosclerotic plaque characteris-
tics. Circulating leukocytes and platelets are highly reac-
tive to exogenous stimuli such as microbial toxins, nota-
bly endotoxins, lipopolysaccharides (LPS), cytokines, 
and immune mediators. The stimulated cells undergo 
molecular and cellular changes and secrete active pro-
inflammatory molecules that induce endothelial adhe-
sion molecules and facilitate transmigration of blood 
cells  [2–4] . Blood cell activation may therefore play an 
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 Abstract 
 Background: Atherosclerosis is characterized by infiltration 
of inflammatory cells from circulating blood. Blood cell acti-
vation could play an important role in plaque formation. 
 Methods: We analyzed the relationship between blood cel-
lular markers and quantitative measures of carotid wall com-
ponents in 1,546 participants from the ARIC (Atherosclerosis 
Risk in Communities) Carotid MRI Study. Carotid imaging was 
performed using a gadolinium contrast-enhanced MRI and 
cellular phenotyping by flow cytometry.  Results: Monocyte 
Toll-like receptor (TLR)-2 is associated with larger plaques, 
while CD14, myeloperoxidase, and TLR-4 associate with 
smaller. Platelet CD40L is associated with smaller plaques 
and thinner caps, while P-selectin is associated with smaller 
core size.  Conclusions: Blood cell activation is significantly 
associated with atherosclerotic changes of the carotid wall. 
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important role in contributing to atherogenesis and ath-
eromatous plaque formation. In these exploratory analy-
ses, we postulated that plaque size and composition, mea-
sured by a high-resolution magnetic resonance imaging 
(MRI), are associated with proinflammatory conditions 
of circulating blood cells. To address this, we analyzed 
multiple leukocyte and platelet pro-inflammatory mole-
cules in 1,546 participants from the ARIC (Atherosclero-
sis Risk in Communities) Carotid MRI study using flow 
cytometry.
 To our knowledge, there are no comprehensive studies 
that have explored the relationships between circulating 
blood cells and specific parameters of carotid artery wall 
architecture, as measured by MRI. Therefore, we ana-
lyzed the association of multiple cellular pro-inflamma-
tory molecules with carotid artery wall characteristics in 
the large biracial ARIC Carotid MRI Study cohort.  
 Methods 
 Study Design and Participants  
 The ARIC study is a multicenter, prospective cohort study of 
atherosclerosis among 15,792 African-American and Caucasian 
people aged 45–64 years at recruitment (1987–1989)  [5] . The 
ARIC carotid MRI Study was conducted between 2004 and 2006 
as a cross-sectional sub-study and was designed to advance our 
understanding of cellular factors and their association with ath-
eromatous plaques. To increase the prevalence of the informative 
plaques while maintaining the ability to make population-based 
inferences, a stratified sampling plan was used. The study sample 
consisted of 2,066 members of the ARIC study cohort, of which 
1,901 underwent a complete MRI examination. Of these 1,901 
participants, 1,769 had sufficient-quality MRI scans, with adher-
ence to the MRI protocol. In addition, 73 participants with 1 or 
more missing values for any of the cellular measurements were 
excluded, leaving 1,634 subjects in the final analyses. With the 
multivariate adjusted models, 88 participants had missing data on 
the adjustment variables, which left a remaining 1,546. The aver-
age age of the substudy participants was 71.2 years; 57% were fe-
male, 81% white, and 19% African American. The prevalence of 
risk factors in the ARIC Carotid MRI study participants has been 
published elsewhere  [6] . The present study was approved by the 
institutional review committees of all participating centers; all 
participants provided informed consent.
 Magnetic Resonance Imaging Protocol  
 MRI studies were performed on a 1.5T scanner (GE Medical 
Systems, Milwaukee, Wisc., USA, at three field centers, and Sie-
mens Medical Solutions, Ehrlangen, Germany, at one field center) 
equipped with a bilateral 4-element phased array carotid coil 
(Machnet, The Netherlands). A 3-dimensional time-of-flight 
magnetic resonance angiogram was acquired through both ca-
rotid bifurcations. Detailed black blood MRI images were then 
acquired through the extracranial carotid bifurcation known to 
have a thicker maximum wall by the most recent ultrasonograph-
ic study, unless the technologist determined that the contralat-
eral carotid bifurcation wall appeared thicker on the magnetic 
resonance angiogram. Black blood MRI was achieved using a car-
diac-gated, 2-dimensional, double-inversion recovery fast spin-
echo sequence, with the inversion time set to suppress the signal 
of blood. Each participant received an intravenous injection of 
gadodiamide (Omniscan, GE Amersham, UK), 0.1 mmol/kg 
body weight, using a power injector. Sixteen transverse T 1 -weight-
ed black blood MRI images (acquired resolution, 0.51  ! 0.58  ! 
2.00 mm 3 ; total longitudinal coverage, 3.2 cm) were oriented per-
pendicular to the vessel and centered at the thickest part of the 
internal or common carotid artery wall. These 16 slices were ac-
quired 5 min after the injection through the thicker carotid artery 
using a 2-dimensional double-inversion recovery fast spin-echo 
sequence, with the inversion time set to suppress the signal of the 
contrast-enhanced blood pool.
 Image Analysis 
 The MRIs were analyzed by seven experts, blinded to the clin-
ical and laboratory characteristics of the study population. All 
examinations were assessed for image quality and protocol adher-
ence; examinations that failed to follow these protocols were not 
analyzed.
 Slices were numbered 1 through 16 from proximal to distal; 
only 8 slices, centered around the slice with the thickest wall, were 
analyzed. The plaque components were analyzed on the postcon-
trast black blood MRI series based on the ability of gadolinium 
enhancement to delineate and enable quantitative size measure-
ments of the fibrous cap  [7] ; contours were drawn to delineate the 
outer wall, the lumen, the lipid core, and calcification. The total 
vessel area included the lumen, the intima, the media, and the 
adventitia. Wall area was calculated as the difference between to-
tal vessel area and lumen area. The derived MRI variable, Nor-
malized Wall Index (NWI), was calculated by dividing the wall 
area by the total vessel area. Reliability coefficients (R) for the 
previously mentioned MRI variables were obtained from an in-
ternal reliability study  [8] . Generally, the reliability for most MRI 
variables varied from excellent (R  1 0.75) to fair to good (0.40  ! R 
 ! 0.75). However, the limited resolution of the 1.5-T MRI scanner 
may have contributed to the lower reliability of measurements re-
lated to relatively small structural features, such as the fibrous cap 
thickness. Although reliability based on repeated readings was 
fair to good for cap thickness measures (R = 0.60), reliability based 
on repeated scans was poor for cap thickness (R = 0.38). A detailed 
description of the image analysis methods for the ARIC Carotid 
MRI Study was published previously  [8] .
 Flow Cytometry 
 Blood samples were collected in Cyto-Chex  BCT vacutainer 
tubes (Streck, Omaha, Nebr., USA) containing EDTA and a cell 
membrane stabilizer for blood cells at the field centers  [9] . Sam-
ples were shipped overnight and analyzed immediately after ar-
rival by flow cytometry  [10] . We measured the following markers: 
(1) platelet CD41 (glycoprotein IIb, GP-IIb), CD61 (GP-IIIa), 
CD62P (P-selectin) and CD154 (CD40 ligand); (2) monocyte 
CD14 (LPS receptor), CD162 (P-selectin glycoprotein ligand-1 or 
PSGL-1), Toll-like receptors 2 (TLR2; CD282) and 4 (TLR4; 
CD284), and myeloperoxidase (MPO), and (3) platelet-monocyte 
aggregates (PMA). Platelets were identified and distinguished 
from non-platelet events (red blood cells and leukocytes) by their 
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characteristic forward light scatter (FS) versus side scatter (SSC) 
characteristics (log FS; log SSC) and their fluorescence from FL1 
(CD61 and CD41), in the log-log dot plot of FS versus CD61 or 
CD41. Monocytes were identified by a specific CD14-PC5 stain-
ing, and PMAs were analyzed by double staining with anti-CD14 
and anti-CD41 and were defined as a population of CD14+ mono-
cytes that are also CD41+. A detailed description of the flow cy-
tometry protocols has been published elsewhere  [10] . Data are 
presented as proportions of cells expressing the antigen (%) and/
or the relative levels of antigen expression assessed by the median 
fluorescent intensity (MFI). 
 Statistical Analysis 
 All analyses were based on methods appropriate for a stratified 
random sampling. In particular, all analyses were weighted by the 
inverse of the sampling fractions in the 8 sampling strata (4 field 
centers  ! 2 IMT groups). The sampling fractions were based on 
those persons screened for participation. Those who actually par-
ticipated were analyzed as a domain for calculating variances and 
confidence intervals (CIs) of estimators. Analyses were conducted 
using computer software for descriptive statistics (SAS, version 
9.1; SAS Institute Inc., Cary, N.C., USA) or for domain analysis 
(SUDAAN; RTI International, The Research Triangle, N.C., 
USA). Finite population correction factors were not applied. Tests 
of differences in weighted means or proportions between groups 
were from weighted linear or logistic regression models that ac-
counted for the sampling. Adjusted means and proportions by 
subgroup of interest were calculated using the SUDAAN RE-
GRESSION procedure for continuous variables and the LOGIS-
TIC procedure for dichotomous variables, with predicted values 
calculated as sample means of the adjusting variables. Wall thick-
ness and wall volume were analyzed in the full data set of 1,546 
participants. Because of the resolution constraints of the MRI 
scan, we restricted consideration of lipid core to the 1,064 par-
ticipants whose maximum wall thickness was  6 1.5 mm (weight-
ed percentage, 62%). Only four lipid cores were excluded using 
this threshold. Measures of lipid core volume and area and fibrous 
cap thickness were analyzed as continuous variables among those 
513 participants with a lipid core. An additional analysis consid-
ered correlates of lipid core presence as a dichotomous variable. 
Standardized regression coefficients are presented for linear and 
logistic regression models, standardizing by one SD of exposure 
and outcome (for continuous outcomes), with adjustment for age, 
race, and sex. 
 Results 
 Association of Cellular Markers and Aggregates with 
Carotid Wall Volume 
 We investigated the relationships of blood platelet and 
leukocyte markers and cellular aggregates with continu-
ous carotid wall thickness or volume measures ( table 1 ).
 Monocyte TLR-2 was positively associated with total 
wall volume, while monocyte CD14 (MFI), TLR-4 (% and 
MFI), MPO (MFI), and platelet CD40L (MFI) were nega-
tively associated with total wall volume. When the analy-
sis was restricted to maximum segmental wall thickness, 
only monocyte TLR-2 remained positively associated.  
 Association of flow cytometry markers (weighted 
mean values) with wall thickness was further analyzed by 
comparing the markers in participants with maximal 
wall thickness  ! 1.5 vs.  6 1.5 mm. Subjects with maximal 
wall thickness  6 1.5 mm had statistically significantly 
higher frequencies of platelets expressing CD40L (3  8 2.7 
vs. 2.6  8 2, p  ! 0.01), and lower monocyte intracellular 
MPO levels (89.6  8 24.5 vs. 96.6  8 25.7, p  ! 0.001).  There 
was no difference in the mean levels of other flow cytom-
etry markers between participants with wall thickness 
 6 1.5 vs.  ! 1.5 mm. 
 Association of Cellular Markers and Aggregates with 
Fibrous Cap Thickness 
 Analysis of the relationship between fibrous cap mea-
sures and flow cytometry measures was restricted to par-
ticipants with maximal wall thickness  6 1.5 mm and 
Table 1. A RIC Carotid MRI Study: relationship between con-











GPIIb, MFI 0.06 (0.19) –0.03 (0.48)
GPIIIa, MFI –0.03 (0.52) –0.01 (0.84)
P-selectin, % 0.02 (0.60) 0.01 (0.74)
P-selectin, MFI 0.003 (0.95) –0.03 (0.36)
CD40L, % 0.07 (0.09) 0.04 (0.25)
CD40L, MFI –0.1 (0.03) –0.04 (0.17)
Monocytes
CD14, MFI –0.14 (0.004) –0.02 (0.62)
TLR-2, % 0.11 (0.03) 0.07 (0.04)
TLR-2, MFI 0.09 (0.06) 0.06 (0.12)
TLR-4, % –0.12 (0.02) –0.01 (0.86)
TLR-4, MFI –0.13 (0.007) –0.002 (0.95)
PSGL-1, MFI 0.07 (0.15) 0.01 (0.80)
MPO, MFI –0.10 (0.03) –0.05 (0.15)
Cellular aggregates
PMA, % 0.06 (0.26) 0.02 (0.59)
R esults are adjusted for age, race, gender, LDL-C, HDL-C, TG, 
CRP, BMI, waist/hip, diabetes, smoking, lipid-lowering therapy, 
and antihypertensive medications. 
Standardized beta coefficients, p value in parentheses. Num-
ber of SD differences in MRI variables associated with 1 SD incre-
ment in flow cytometry measures. 
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presence of a lipid core. After adjustments for age, race, 
sex, and conventional cardiovascular risk factors, only 
platelet CD40L levels were inversely associated with mean 
cap thickness and mean minimum cap thickness, while 
platelet-monocyte aggregates (%) were associated with 
greater mean cap thickness ( table 2 ).
 Association of Cellular Markers and Aggregates with 
Lipid Core Size 
 Table 3 shows the relationship between lipid core and 
flow cytometry measures, restricted to participants with 
maximum wall thickness  1 1.5 mm. Only the platelet level 
of P-selectin was statistically significantly associated (in-
versely) with total lipid core volume, and the significance 
was borderline with maximum lipid core area. Partici-
pants who had lipid core had statistically significantly low-
er platelet GPIIb levels (77.5  8 12.9 vs. 79.7  8 11.5, p = 
0.02) and monocyte PSGL-1 levels (110.8  8 15.3 vs. 113.7 
 8 15.5, p = 0.01) than those without a detectable lipid core.
 Discussion 
 In this cross-sectional, population-based study, we ex-
amined the association of circulating blood cellular 
markers with atherosclerotic plaque size and composi-
tion as measured by MRI. For the thickest area of the ca-
rotid wall, we assessed plaque size, expressed as total wall 
thickness and volume, and plaque composition, assessed 
as lipid core quantity and fibrous cap thickness. We found 
that several pro-inflammatory markers of circulating 
blood monocytes and platelets were associated with 
plaque size and composition. Notably, monocyte TLR-2 
was associated with greater plaque size, heterotypic cell 
aggregates were associated with greater fibrous cap thick-
ness, monocyte MPO and TLR-4 were associated with 
smaller plaque size, and platelet activation markers were 
inversely associated with both plaque size and the size of 
plaque components. There was also a weak inverse asso-
ciation between platelet GPIIb, monocyte PSGL-1, and 
Table 2.  ARIC Carotid MRI Study: flow cytometry profile of  fi-
brous cap measures and flow cytometry measures, restricted to par-










GP IIb, MFI –0.02 (0.24) –0.003 (0.81)
GP IIIa, MFI –0.03 (0.15) 0.01 (0.69)
P-selectin, % 0.01 (0.67) 0.01 (0.67)
P-selectin, MFI 0.01 (0.60) 0.004 (0.80)
CD40L, % –0.01 (0.73) –0.00 (0.99)
CD40L, MFI –0.03 (0.04) –0.02 (0.05)
Leukocytes
CD14, MFI –0.003 (0.85) –0.01 (0.39)
TLR-2, % 0.02 (0.18) 0.01 (0.45)
TLR-2, MFI 0.01 (0.29) –0.002 (0.85)
TLR-4, % 0.03 (0.12) 0.01 (0.26)
TLR-4, MFI 0.001 (0.94) 0.001 (0.96)
PSGL-1, MFI 0.02 (0.30) 0.003 (0.85)
MPO, MFI 0.01 (0.55) –0.003 (0.86)
Cellular aggregates
PMA, % 0.03 (0.03) 0.02 (0.13)
R esults are adjusted for age, race and gender, LDL-C, HDL-C, 
TG, CRP, BMI, waist/hip, diabetes, smoking, lipid-lowering ther-
apy, antihypertensive medications (fibrous cap also adjusted for 
wall thickness). 
Standardized beta coefficients, p value in parentheses. Num-
ber of SD differences in MRI variables associated with 1 SD incre-
ment in flow cytometry measures. 
Table 3. A RIC Carotid MRI Study: flow cytometry profile for 
continuous lipid core measures restricted to participants with 










GP IIb, MFI –0.01 (0.74) –0.002 (0.62)
GP IIIa, MFI 0.02 (0.65) –0.001 (0.90)
P-selectin, % –0.04 (0.18) –0.01 (0.21)
P-selectin, MFI –0.08 (0.03) –0.01 (0.05)
CD40L, % 0.01 (0.72) 0.004 (0.30)
CD40L, MFI 0.03 (0.25) 0.003 (0.32)
Monocytes
CD14, MFI 0.06 (0.10) 0.01 (0.06)
TLR-2, % –0.00 (0.99) 0.003 (0.53)
TLR-2, MFI –0.02 (0.68) 0.002 (0.74)
TLR-4, % –0.01 (0.75) –0.00 (0.97)
TLR-4, MFI 0.04 (0.22) 0.004 (0.44)
PSGL-1, MFI –0.01 (0.83) –0.001 (0.77)
MPO, MFI –0.01 (0.66) 0.001 (0.83)
Cellular aggregates
PMA, % –0.03 (0.35) –0.01 (0.15)
R esults are adjusted for age, race and gender, LDL-C, HDL-C, 
TG, CRP, BMI, waist/hip, diabetes, smoking, lipid-lowering ther-
apy, antihypertensive medications (lipid core also adjusted for to-
tal wall volume). 
Standardized beta coefficients, p value in parentheses. Num-
ber of SD differences in MRI variables associated with 1 SD incre-
ment in flow cytometry measures. 
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plaque lipid core. These results suggest the involvement 
of different pro-inflammatory cellular markers with 
plaque formation, fibrous deposition, and tissue necrosis. 
It may be speculated that blood cell inflammatory mol-
ecules may impact endothelium, thereby altering trans-
migration of monocytes. Furthermore, once entering the 
vascular wall, different monocyte inflammatory mole-
cules may contribute to plaque formation, plaque core ne-
crosis/apoptosis, and cap matrix deposition.
 Activation of monocytes and macrophages is an im-
portant step in many inflammatory diseases including 
atherosclerosis. Monocytes recruited through the acti-
vated endothelium differentiate into macrophages, which 
take in lipids to become foam cells, an early step in ath-
erogenesis. Several molecules can ligate TLRs on these 
cells leading to inflammation and tissue damage. TLR-2 
and TLR-4 play key roles in initiating inflammatory re-
sponses, and their upregulation in atherosclerotic lesions 
has been documented in animal models and in humans 
 [11–13] . Upon activation, TLRs use signaling pathways 
leading to the production of pro-inflammatory cytokines 
and chemokines. The receptor complex of CD14 and 
TLR-4 in peripheral monocytes appears to be the princi-
pal receptor complex of LPS, mediating activation of 
transcription factor NF-B, which plays an important 
role in inducing synthesis of proinflammatory cytokines 
 [14–16] .
 There are limited data available regarding the associa-
tion of circulating, blood cells expressing TLRs with 
plaque size and composition. In peripheral blood, mono-
cytes represent the predominant site of TLR expression. 
Several studies reported monocyte TLR upregulation in 
relation to coronary artery disease  [17] or heart failure 
after acute myocardial infarction  [18] . Increased TLR-2 
and TLR-4 expression was also reported in monocytes 
from patients with type-1 diabetes, indicating their con-
tribution to a proinflammatory state of this disease  [19] . 
In our study, monocyte TLR-4 expression was indepen-
dently, significantly and inversely associated with wall 
thickness. It is possible that lower TLR-4 levels indicate 
downregulation of TLR-4 due to its internalization, a 
process that was documented in mouse peritoneal mac-
rophages  [20] . In atherosclerotic ApoE –/–  mice, increased 
expression over time of TLR-2 and -4 in atherosclerotic 
plaques and on blood monocytes correlated with the state 
of atherosclerotic disease. Our results, showing an inde-
pendent association of the monocyte TLRs with athero-
sclerotic wall thickness, corroborate these animal studies 
in a large human study.
 CD14 (a monocyte marker) levels on the surface of cir-
culating monocytes and intracellular levels of MPO were 
inversely associated with total wall volume and may be 
explained by the depletion of MPO during monocyte ac-
tivation when MPO is released into plasma  [21] . This pos-
sible explanation is supported by reports that plasma 
MPO levels are increased in coronary heart diseases and 
are associated with increased risk of major atheroscle-
rotic coronary events  [22, 23] . This notion is further 
strengthened by reports that humans with MPO defi-
ciency, or an MPO polymorphism associated with re-
duced MPO expression, have a reduced risk of cardiovas-
cular disease  [24, 25] . Brevetti et al.  [26] reported a re-
duced neutrophil MPO content in coronary artery disease 
patients with peripheral artery disease (PAD), and Mo-
naco et al.  [27] reported that neutrophils were activated 
and depleted of MPO in unstable angina patients.
 Our analysis of platelet markers indicated that platelet 
activation is associated with smaller plaque size, smaller 
core size, and thinner caps. Notably, participants with in-
creased total wall volume, or with increased mean cap 
thickness, had significantly lower expression of platelet 
CD40L. Participants with higher total lipid core volume 
and bigger maximum lipid core area had lower expres-
sion of P-selectin. These findings suggest ongoing platelet 
activation, with P-selectin and CD40L likely being re-
leased into circulation, where they are engaged in an ar-
ray of proatherogenic reactions. 
 Platelets are known to contribute to the progression of 
atherosclerosis  [28] . P-selectin mediates leukocyte trans-
migration into the vessel wall and interacts with PSGL-1 
to activate leukocytes and form platelet-leukocyte aggre-
gates  [29, 31] . Recently, it has been shown that activated 
platelet P-selectin and platelet-monocyte aggregates con-
tribute to progression of atherosclerosis in ApoE –/–  mice 
 [32] .
 Despite a number of studies related to platelet activa-
tion, there are few human studies of correlations between 
platelet activation markers and plaque size/composition. 
In contrast to our study, Koyama et al. reported a positive 
association of platelet P-selectin with carotid artery ath-
erosclerotic wall thickness (intima-media thickness) in 
517 subjects  [33] , while another study showed indepen-
dent association of platelet CD63 but not P-selectin in 105 
patients with diabetes mellitus type 2  [34] . These studies 
differ in how they measure wall thickness and the cut-off 
values used, as well as in study design and patient char-
acteristics. It is possible that lower platelet CD40L and P-
selectin expression in our study may be attributed to en-
gagement of the activation markers to platelet-platelet 
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and platelet-leukocyte aggregate formation. Platelet-leu-
kocyte aggregates are considered to be a more sensitive 
marker of platelet activation than P-selectin because of 
their longer duration in blood circulation  [35] . Hetero-
typic circulating cellular aggregates between platelets 
and leukocytes have been reported in other studies in re-
lation to various diseases and conditions, and they are 
considered to propagate the inflammatory process of ath-
erosclerosis  [36, 37] . In our study, platelet-monocyte ag-
gregates were positively associated with plaque cap thick-
ness. 
 There are several limitations to the current study. 
First, the cross-sectional nature of our study does not al-
low us to establish temporality in the associations. Sec-
ond, even though this is supported by literature, only a 
single plaque was characterized, and we are generalizing 
a single plaque to be representative of the entire cardio-
vascular system. Furthermore, MRI measurement reli-
ability depends on structure size, so cap thickness mea-
surements were not as reliable as wall thickness or core 
size. Finally, multiple statistical associations were exam-
ined, and some of those at nominal significance (p  ! 0.05) 
were likely chance associations. Thus, based on biologic 
and mechanistic plausibility, our results suggest a patho-
genic role of expressed cellular markers, but may under-
estimate the strength of the associations and do not es-
tablish the antecedent role of the markers.
 There are also strengths to the current study. First, the 
study group was selected from the well-characterized, bi-
racial population-based ARIC cohort. To our knowledge, 
this is the largest population-based study investigating 
the relationship of blood cellular markers with quantita-
tive measures of carotid wall components using a gado-
linium contrast-enhanced MRI examination. Second, a 
standardized MRI protocol with a central reading facility 
was used; extensive quality control data were collected, 
allowing assessment of the MRI measures and the ex-
pression of blood platelet and monocyte markers. Finally, 
the present study has technical advantages over previous 
studies, since flow cytometry allows for measuring MPO 
levels in individual cells, independent of the total white 
blood cell count, which is a major factor affecting mea-
surements of serum and plasma MPO levels. 
 In summary, our data indicate that both monocyte 
and platelet activation are associated with distinct carot-
id arterial wall characteristics. Additional studies are 
needed to investigate the relationship between blood cel-
lular markers and atherosclerosis burden.
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